Vanguard Total Stock Market ETF (VTI)

UiPath’s Short interest has climbed to 15.7%, nearly double mid-December levels, prompting some traders to expect a short squeeze if the earnings report beats expectations.

The U.S. Food and Drug Administration is slated to rule on the company’s application seeking approval for Reproxalap by March 16.

Barclays increased the price target on the stock to $4 from $3 and kept an ‘Overweight’ rating on the shares.

A quibble about the name shows a bias among many investors.

According to an Axios report, this effort will see the companies tapping into underused electricity grid capacity, as part of a new coalition named Utilize.

MiNK Therapeutics tied up with an oncology consortium to develop a cell therapy targeting pediatric cancers.

In a note to investors, B. Riley analyst Fedor Shabalin said MSTR’s ‘Digital Credit’ is “meaningfully superior to most traditional yield-oriented alternatives.”

For the fourth quarter, Zevra announced net revenue of $34.1 million, exceeding an analyst estimate of $28.05 million.

The company reported Q4 2025 net loss of $50.0 million vs. net loss of $1.3 million in Q4 2024.

Microsoft said on Monday in a filing with the U.S. SEC that its Executive Vice President of Strategy, Kathleen Hogan, completed the sale on March 6.

HPE said it estimates Q2 revenue to be between $9.6 billion and $10 billion, compared to Wall Street expectations of $9.56 billion, according to data from Fiscal.ai.

The company said its revenues in Q4 came at $125.6 million, lower than $137.7 million in the fourth quarter of 2024, despite railcar deliveries of 1,172 units compared to 1,019 units in the prior year period.

The company sees itself launching air taxis in Arizona, Florida, Idaho, New Jersey, New York, North Carolina, Oklahoma, Oregon, Texas and Utah potentially this year.

The company said that patients treated with povetacicept achieved a 52.0% reduction from baseline in urine protein to creatinine ratio at week 36, meeting the study’s key goal.

According to VP Sendil Palani’s Linkedin profile, he first joined the company in 2009 as a senior financial analyst, before leaving in 2011, and later rejoining the company in 2014.

AN2 Therapeutics shares more than doubled in value on Monday after the company announced a private placement to raise about $40 million.

Cramer cited GE Vernova being sold out of its turbines as the reason behind his calling it a “terrific story.”

A key principle of risk management is something that many investors ignore at their peril.

When stocks begin recovering from a correction, it's usually not the S&P 500 that leads on the way back up.

Retail traders maintained a ‘neutral’ stance on MU amid concerning signals, including Nvidia choosing Korean and Chinese memory suppliers over Micron for its next-gen Vera Rubin hardware.

The right investments can protect your portfolio while maximizing your earnings.

The market is beginning to provide investors with some real buy-the-dip opportunities. I think this ETF delivers the best way to approach it.

It didn't take much, but it had a big impact.

The company said that EC approved Zynyz in combination with carboplatin and paclitaxel for adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal.

Lantheus said that the FDA approved its PYLARIFY TruVu injection.